Prothena price target raised to $85 from $81 at JMP Securities

JMP Securities raised the firm’s price target on Prothena to $85 from $81 and keeps an Outperform rating on the shares following the quarterly results. Headlined by progress on PRX012, Prothena’s broad pipeline continues to advance, the analyst tells investors in a research note.